Revelation Biosciences Files 8-K

TL;DR

REVB filed an 8-K on 6/24, standard reporting.

AI Summary

Revelation Biosciences, Inc. filed an 8-K on June 24, 2024, reporting other events and financial statements. The company, formerly known as Petra Acquisition Inc. until April 23, 2020, is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.

Why It Matters

This filing indicates a routine update on company events and financial reporting, providing transparency to investors about Revelation Biosciences' operational status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K current report, indicating routine corporate events and financial disclosures rather than a significant event that would inherently increase risk.

Key Numbers

• 001-39603 — SEC File Number (Identifies the company's filing with the SEC.)
• 84-3898466 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• REVELATION BIOSCIENCES, INC. (company) — Registrant
• Petra Acquisition Inc. (company) — Former company name
• 20200423 (date) — Date of name change
• 20240624 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• San Diego, California (location) — Business address

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share REVB The Nasdaq Stock Mar
• $12,075.00 — of common stock at an exercise price of $12,075.00 per share REVBW The Nasdaq Stock Ma
• $2.39 — r a 1/30th of a share of common stock @ $2.39 per share. Class D Warrants (CUSIP: 7

Filing Documents

• revb-20240624.htm (8-K) — 50KB
• revb-ex99_1.htm (EX-99.1) — 23KB
• 0000950170-24-076761.txt ( ) — 228KB
• revb-20240624.xsd (EX-101.SCH) — 48KB
• revb-20240624_htm.xml (XML) — 7KB

01 Other Events

Item 8.01 Other Events. Pursuant to section 3(b) of each of the Class C Common Stock Purchase Warrant originally issued by Revelation Biosciences, Inc. (the "Company") on February 13, 2023, and the Class D Common Stock Purchase Warrant originally issued by the Company on February 5, 2024 (individually a "Warrant" and collectively the "Warrants"), the Exercise Price (as defined in the Warrants) has been adjusted as follows: Class C Warrants (CUSIP: 76135L408) are each exercisable for a 1/30th of a share of common stock @ $2.39 per share. Class D Warrants (CUSIP: 76135L143) are each exercisable for a share of common stock @ $2.39 per share. Until the adjustments have been made through the Depository Trust Corporation ("DTC") system, Cede & Co. (a nominee of DTC) is unable to process exercises of the Warrants at the adjusted exercise price. Until such time, Warrants may be exercised by returning the Notice of Warrant Exercise in the form attached to the Warrants and reproduced as Exhibit 99.1 to this Current Report to the Warrant Agent as follows: Continental Stock Transfer & Trust Company 1 State Street, 30th Floor New York, NY 10004 Attn: Compliance Dept. Email: Compliance@continentalstock.com Delivery of Warrant Shares (as defined in the Warrants) shall be made directly through DWAC instructions provided by the Warrant holder. Upon receipt of the Warrant Notice of Exercise, the Warrant Agent shall provide wire transfer instructions and obtain DWAC instructions for settlement. Except as provided herein, the terms and conditions of the Warrants (including the number of shares of common stock for each warrant is exercisable) remain in full force and effect, including, without limitation, the mechanics of exercise thereof.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Notice of Warrant Exercise 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVELATION BIOSCIENCES, INC. Date: June 24, 2024 By: /s/ Chester S. Zygmont, III Chester S. Zygmont, III Chief Financial Officer (principal financial and accounting officer)

View Full Filing

View this 8-K filing on SEC EDGAR